Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

BRAF mutations in papillary carcinomas of the thyroid


BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas (40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1



v-raf murine sarcoma viral oncogene homologe B1

MAP kinase:

mitogen-activated protein kinase

MEK kinase:

mitogen-activated protein kinase kinase


  • Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP and Ballotti R . (2000). EMBO J., 19, 2900–2910.

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA. (2002). Nature, 417, 949–954.

  • Halaban R . (2000). Pigment Cell Res., 13, 4–14.

  • Lazzereschi D, Minicione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S and Colletta G. . (1997). J. Exp. Clin. Cancer Res., 16, 325–332.

  • Learoyd DL, Messian M, Zedenius J and Robinson BG . (2000). World J. Surg., 24, 923–933.

  • Ledent C, Parmentier M, Maenhaut C, Taton M, Pirson I, Lamy F, Roger P and Dumont JE . (1991). Thyroidology, 3, 97–101.

  • Manenti G, Pilotti S, Re FC, Della Porta G and Pierotti MA . (1994). Eur. J. Cancer, 30, 987–993.

  • Naoki K, Chen TH, Richards WG, Sugarbaker DJ and Meyerson M . (2002). Cancer Res., 62, 7001–7003.

  • Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S and Sozzi G . (1996). Genes Chromosom. Cancer, 16, 1–14.

  • Sebolt-Leopold JS . (2000). Oncogene, 27, 6594–6599.

  • Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB and Asa SL . (1999). Surgery, 125, 46–52.

  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Toshihiko Fukushima.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fukushima, T., Suzuki, S., Mashiko, M. et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22, 6455–6457 (2003).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • BRAF
  • RAS
  • papillary carcinoma of the thyroid
  • follicular carcinoma of the thyroid
  • MAP kinase pathway

This article is cited by


Quick links